Pioneer Medical Associates

Wegovy: a game-changing anti-obesity medication

Wegovy is an injectable medication that was developed by Novo Nordisk, a Danish pharmaceutical company. Semaglutide, the active ingredient in Wegovy, was initially designed as a treatment for type 2 diabetes

Clinical trials have shown that Wegovy can help with weight loss and overall health improvement. In trials, patients with obesity and without diabetes taking Wegovy alongside a fitness and nutrition plan saw upwards of 15% total body weight loss on average—some individuals losing up to 33%.

More research is needed to understand the full benefits of semaglutide and other GLP-1 medications. So far, studies have proposed evidence for GLP-1 medications having multiple positive biological effects, such as reducing neuroinflammation, promoting nerve growth, improving heart function, suppressing appetite, delaying gastric emptying, regulating blood lipid metabolism and reducing fat deposition.

Appointment Request